Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

59766

Next Previous
X
Search
Drug Profile

59766

Alternative Names: Anti-COVID-19 T cell therapy - Tevogen Bio; TVGN-489

Latest Information Update: 01 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tevogen Bio
  • Class Antivirals; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I COVID 2019 infections
  • Clinical Phase Unknown Post acute COVID 19 syndrome
  • Preclinical Haematological malignancies; Lymphoma; Multiple sclerosis; Nasopharyngeal cancer; Solid tumours

Most Recent Events

  • 25 Jun 2024 Efficacy and adverse events data from the phase I trial in COVID-1019 infection released by Tevogen Bio
  • 20 Mar 2024 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by Tevogen Bio
  • 21 Feb 2024 Tevogen Bio plans a clinical trial in Post-acute-COVID-19-syndrome in March 2024 (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top